Abcuro: Funding, Investors & Team (Sep 2026)
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.
Abcuro has raised $147M across 3 funding rounds on record, the most recent a Series D of $66.0M announced in Aug 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Abcuro Company Profile and Key Stats
Latest funding round on record: Aug 2026.
Abcuro Funding Rounds
Abcuro raised $42.0M in a Series A announced in Jan 2021.
5.6 years later, an undisclosed round of $39.4M was announced in Aug 2026.
A Series D of $66.0M was announced in Aug 2026.
Abcuro Investors
24 investors are recorded in total; the 5 named above are those the record identifies.
Abcuro Founders and Leadership Team
Contact details for the Abcuro team: 3 of 3 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Abcuro Funding Compared to Other Biotechnology Startups
Abcuro's latest round of $66.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Abcuro in Biotechnology and Newton
Companies Similar to Abcuro
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Abcuro Funding FAQs
What does Abcuro do?
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.
How much funding has Abcuro raised?
Abcuro has raised $147M across 3 rounds on record. The most recent is a Series D of $66.0M announced in Aug 2026.
When did Abcuro last raise funding?
Abcuro's most recent funding round on record is a Series D of $66.0M, announced in Aug 2026.
Who has invested in Abcuro?
Investors on record for Abcuro include RA Capital Management, BlackRock, New Enterprise Associates, Soleus Capital, Foresite Capital. FundedIQ records 24 investors in total.
Who is the CEO of Abcuro?
Alex Martin is listed as Active Chairman, CEO, and Life Coach at Abcuro.
Where is Abcuro headquartered?
Abcuro is based in Newton, Massachusetts, United States.
How many employees does Abcuro have?
Abcuro is in the 11-50 employee band.
When was Abcuro founded?
Abcuro was founded in 2015.
How does Abcuro's funding compare to other Biotechnology startups?
Abcuro's latest round of $66.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Abcuro Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Abcuro is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.